Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background: Placebo-controlled trials showed that both benzodiazepines (BDZ) and antidepressant drugs (AD) are effective in treating anxiety disorders. However, in the last years a progressive shift in the prescribing pattern from BDZ to newer AD has taken place. The aim of this systematic review and meta-analysis is to analyze whether controlled comparisons support such a shift. Methods: CINHAL, the Cochrane Library, MEDLINE, PubMed and Web of Science were searched from inception up to December 2012. A total of 22 studies met the criteria for inclusion. They were mostly concerned with tricyclic antidepressants (TCA; 18/22) and involved different anxiety disorders. In order to reduce clinical heterogeneity, only the 10 investigations that dealt with the comparison between TCA and BDZ in panic disorder were submitted to meta-analysis, whereas the remaining papers were individually summarized and critically examined. Results: According to the systematic review, no consistent evidence emerged supporting the advantage of using TCA over BDZ in treating generalized anxiety disorder (GAD), complex phobias and mixed anxiety-depressive disorders. Indeed, BDZ showed fewer treatment withdrawals and adverse events than AD. In panic disorder with and without agoraphobia our meta-analysis found BDZ treatments more effective in reducing the number of panic attacks than TCA (risk ratio, RR = 1.13; 95% CI = 1.01-1.27). Furthermore, BDZ medications were significantly better tolerated than TCA drugs, causing less discontinuation (RR = 0.40; 95% CI = 0.20-0.57) and side effects (RR = 0.41; 95% CI = 0.34-0.50). As to newer AD, BDZ trials resulted in comparable or greater improvements and fewer adverse events in patients suffering from GAD or panic disorder. Conclusions: The change in the prescribing pattern favoring newer AD over BDZ in the treatment of anxiety disorders has occurred without supporting evidence. Indeed, the role and usefulness of BDZ need to be reappraised.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, benzodiazepines are not indicated for the long-term treatment of anxiety, insomnia, or stress, for which they are most often prescribed [81–83].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [82]
In the citing paper
“Antipsychotics rapidly eliminated or rapidly dissociated from the D2 receptors (i.e., clozapine, quetiapine) [161, 162] are known to have greater risks of rebound when medication is decreased, switched, or discontinued [13, 154, 156, 157, 163].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [162]
In the citing paper
“In a systematic review, benzodiazepines were associated with fewer withdrawals and adverse events than AD in anxiety disorders.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“Such change has occurred without any supporting evidence.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
In the citing paper
“In panic disorder, whether accompanied by agoraphobia or not, benzodiazepine treatment was more effective in reducing the number of panic attacks than antidepressant medications.75”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [75]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Davis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Kahn, R. J. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800010081010 · Cited by 278
Klerman, G. L. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.2.191 · Cited by 229
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
THE NOTTINGHAM STUDY OF NEUROTIC DISORDER: COMPARISON OF DRUG AND PSYCHOLOGICAL TREATMENTS
Tyrer, P. J., Murphy, S., Kingdon, D., Brothwell, J. A., Gregory, S., Seivewright, N., Ferguson, B. G., Barczak, P., Darling, C., & Johnson, A. L. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92535-4 · Cited by 166
Cost of anxiety disorders in Europe
Andlin‐Sobocki, P., & Wittchen, H. ‐. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01196.x · Cited by 165
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Self-citationHoehn‐Saric, R., McLeod, D. R., & Zimmerli, W. D. (1988) · PubMed · Cited by 156
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Möller, H.-J., Volz, H.-P., Reimann, I. W., & Stoll, K.-D. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00011 · Cited by 147
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135
Clinimetrics and Clinical Psychometrics: Macro- and Micro-Analysis
Tomba, E., & Bech, P. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341757 · Cited by 124
Self-citationSchweizer, E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130053009 · Cited by 120
Pirraglia, P. A., Stafford, R. S., & Singer, D. E. (2003) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v05n0402 · Cited by 109
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
Self-citationSkinner, R. D., Rasco, L., Fitzgerald, J., Karson, C. N., Matthew, M., Williams, D. K., & García‐Rill, E. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:3<122::aid-da4>3.0.co;2-m · Cited by 88
Andersch, S., Rosenberg, N. K., Kullingsjö, H., Ottosson, J. ‐., Bech, P., Bruun‐Nansen, J., Hanson, L., Lorentzen, K., Mellergård, M., Rasmussen, S., et al. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03097.x · Cited by 81
Fava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80
Self-citationThe Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties
Guidi, J., Fava, G. A., Bech, P., & Paykel, E. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000317532 · Cited by 79
Self-citationSerum trace elements in animal models and human depression. Part I. Zinc
Nowak, G., ba, A. Z., Dudek, D., Krośniak, M., Szymaczek, M., & Schlegel-Zawadzka, M. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199903)14:2<119::aid-hup77>3.0.co;2-1 · Cited by 78
Perugi, G., Akiskal, H. S., Toni, C., Simonini, E., & Gemignani, A. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00433-5 · Cited by 73
Baldwin, D. S., Allgulander, C., Bandelow, B., Ferre, F., & Pallanti, S. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.624548 · Cited by 69
The Spectrum of Anxiety Disorders in the Medically Ill
Fava, G. A., Porcelli, P., Rafanelli, C., Mangelli, L., & Grandi, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06000blu · Cited by 67
Self-citationHolding the Line against Diagnostic Inflation in Psychiatry
Batstra, L., & Frances, A. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000331565 · Cited by 64
Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder
Hindmarch, I. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02085.x · Cited by 61
Response of panic disorder to fixed doses of alprazolam or imipramine
UHLENHUTH, E. H., Matuzas, W., Glass, R. M., & Easton, C. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90009-8 · Cited by 56
Nardi, A. E., Freire, R. C., Mochcovitch, M. D., Amrein, R., Levitan, M. N., King, A. L., Valença, A. M., Veras, A. B., Paes, F., Sardinha, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823fe4bd · Cited by 56
Systematic Overview of Drug Interactions with Antidepressant Medications
Nieuwstraten, C., Labiris, N. R., & Holbrook, A. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100506 · Cited by 56
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:3<107::aid-da2>3.0.co;2-t · Cited by 56
TAYLOR, C. B., HAYWARD, C., KING, R., EHLERS, A., MARGRAF, J., MADDOCK, R., CLARK, D., ROTH, W. T., & AGRAS, W. S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199004000-00006 · Cited by 55
A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder.
Rizley, R. C., Rj, K., McNair, D. M., & Frankenthaler, L. M. (1986) · PubMed · Cited by 48
Hackett, D., Haudiquet, V., & Salinas, E. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00046-4 · Cited by 47
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45
Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
Self-citationPsychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
Nardi, A. E., Valença, A. M., Freire, R. C., Mochcovitch, M. D., Amrein, R., Sardinha, A., Levitan, M. N., Nascimento, I., de-Melo-Neto, V. L., King, A. L., et al. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011000400015 · Cited by 39
Antidepressant-associated mania: a study of anxiety disorders patients
Levy, D. M., Kimhi, R., Barak, Y., Aviv, A., & Elizur, A. (1998) · Psychopharmacology · doi:10.1007/s002130050562 · Cited by 35
Sheikh, J. I., & Swales, P. J. (1999) · The International Journal of Psychiatry in Medicine · doi:10.2190/kqej-mqjr-vk3d-f3hv · Cited by 35
Berney, P., Halperin, D., Tango, R., Daeniker-Dayer, I., & Schulz, P. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4323 · Cited by 32
Treatment of Cyclothymic Disorder: Commentary
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000322234 · Cited by 32
Benzodiazepines and anxiety sensitivity in panic disorder
Fava, G. A., Grandi, S., Belluardo, P., Savron, G., Raffi, A. R., Conti, S., & Saviotti, F. M. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90118-x · Cited by 32
Self-citationPsychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
Nardi, A. E., Valença, A. M., Freire, R. C. R., et al. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500020 · Cited by 28
Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice
Allsopp, L. F., Cooper, G. L., & Poole, P. H. (1984) · Current Medical Research and Opinion · doi:10.1185/03007998409109561 · Cited by 27
A Guide to Benzodiazepine Selection. Part II: Clinical Aspects
Teboul, E., & Chouinard, G. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600117 · Cited by 25
Olver, J. S., Burrows, G. D., & Norman, T. R. (1999) · CNS Drugs · doi:10.2165/00023210-199912030-00001 · Cited by 22
Lepola, U. M., Rimón, R., & Riekkinen, P. J. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300820-00006 · Cited by 22
Deltito, J. A., Argyle, N., & KLERMAN, G. L. (1991) · PubMed · Cited by 21
Clinical Guide to Psychotropic Medications
Dubovsky, S. L. (2005) · Medical Entomology and Zoology · Cited by 19
Fava, G. A. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000328768 · Cited by 19
Self-citationAntidepressant-Induced Tardive Dysphoria
El-Mallakh, R. S., Gao, Y., Briscoe, B. T., & Roberts, R. J. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000316799 · Cited by 13
Pattern of placebo response in panic disorder.
Shear, M. K., Leon, A. C., Pollack, M. H., Rosenbaum, J. F., & Keller, M. B. (1995) · PubMed · Cited by 13
Leckman, J. F. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345543 · Cited by 12
Feltner, D. E., Harness, J. A., Brock, J., Sambunaris, A., Cappelleri, J. C., & Morlock, R. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00075.x · Cited by 11
Alprazolam and amitryptyline: a double blind comparison of anxiolytic and anti-depressant activity.
Rj, D., & Daly, I. (1983) · PubMed · Cited by 9
Research works printed but not linked: 1
- 10.1159%2f000334112 · DOI
Cited by
Sex differences in anxiety and depression clinical perspectives
Altemus, M., Sarvaiya, N., & Neill Epperson, C. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.05.004 · Cited by 1,413
“Of all of the anxiety disorders, panic disorder is particularly responsive to benzodiazepine treatment (Offidani et al., 2013).”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Metadata
- Authors
- Offidani, E., Guidi, J., Tomba, E., & Fava, G. A.
- Affiliations
- University of Bologna (IT)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 82
- Issue
- 6
- Pages
- 355-362
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2058854656
- Semantic Scholar
- 51250bb52dc9a5838fd9cb633760bcbf3bfe6a5e
- Cited by
- 166
- References
- 64
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 17 · 2023: 8 · 2022: 12 · 2021: 6 · 2020: 17 · 2019: 12 · 2018: 16 · 2017: 17 · 2016: 13 · 2015: 16 · 2014: 17 · 2013: 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- benzodiazepines, antidepressants, anxiety disorders, tricyclic antidepressants, panic disorder, generalized anxiety disorder, mixed anxiety-depressive disorder, treatment efficacy, tolerability, adverse events, treatment withdrawal, prescribing patterns
- MeSH terms
- Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety Disorders, Benzodiazepines, Humans, Obsessive-Compulsive Disorder, Practice Patterns, Physicians', Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.